NVRO 241220 30.00C (NVRO241220C30000) Stock Options, News & Quotes

US OptionsDetailed Quotes

NVRO241220C30000

Watchlist

2.12
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

RBC Capital Remains a Hold on Nevro Corp (NVRO)
TipRanksDec 19 05:31 ET · Ratings
Where Nevro Stands With Analysts
BenzingaDec 18 15:01 ET
Nevro Is Maintained at Hold by Truist Securities
Dow JonesDec 18 10:33 ET · Ratings
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4.7
Moomoo NewsDec 18 08:33 ET · Ratings
Nevro Price Target Lowered to $4.70 From $7 at Truist
TipRanksDec 18 07:37 ET
Express News | Nevro Corp : Truist Securities Cuts Target Price to $4.7 From $7
ReutersDec 18 07:33 ET

Comments

Trytosaveabit

Nov 12 06:07

Update

$Nevro (NVRO.US)$ Reuters
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally

Stock_Drift

Nov 11 16:19

After Hours Ticks. 5:18pm

$Impact BioMedical (IBO.US)$ $Adicet Bio (ACET.US)$ $Zoomcar Holdings (ZCAR.US)$ $Ryde Group (RYDE.US)$ $Foresight Autonomous (FRSX.US)$ $Check-Cap (CHEK.US)$ $Nvni Group (NVNI.US)$ $Bridger Aerospace (BAER.US)$ $Taoping (TAOP.US)$ $Scienjoy (SJ.US)$ $Nevro (NVRO.US)$ $Taysha Gene Therapies (TSHA.US)$ $MultiMetaVerse (MMV.US)$ $XBP Europe Holdings (XBP.US)$

Jaguar8

Sep 24 07:02

NEWS

$Nevro (NVRO.US)$
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...

Newbee4

Aug 8 06:22

Do you have any thoughts on this?

$Nevro (NVRO.US)$ @Trytosaveabit

Moomoo AI

Feb 25 07:35

Nevro's low P/S ratio may be due to its poor revenue outlook. Shareholders accept this as they anticipate no future revenue surprises. These conditions could continue to limit the share price.

Benign Growth For Nevro Corp. (NYSE:NVRO) Underpins Its Share Price